We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHemogenyx Share News (HEMO)

Share Price Information for Hemogenyx (HEMO)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.634
Bid: 1.632
Ask: 1.664
Change: 0.005 (0.31%)
Spread: 0.032 (1.961%)
Open: 1.698
High: 1.70
Low: 1.634
Prev. Close: 1.629
HEMO Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Mind Gym revenue recovers; Dispersion buys Accru

Mon, 18th Oct 2021 15:12

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

----------

Mind Gym PLC - London-based training and management development company - Expects revenue of GBP24.1 million in the six months ended September 30, up 66% year-on-year from GBP14.5 million. Revenue remained slightly above the GBP23.9 million reported in the comparative pre-Covid period, two years earlier. Says 82% of income was "digitally enabled". Continues to invest in its technological capacities ahead of the planned launches of its new digital products. Expects to release its interim results on December 3.

----------

Dispersion Holdings PLC - decentralised finance investor using blockchain and cryptocurrencies to remove financial intermediaries from transactions - Acquires Accru Finance Ltd for GBP8.8 million, to be paid via the issue of 250 million new company shares. Accru's sellers will then hold a 29% stake in Dispersion. The company says Accru plans to launch: "the first internationally-regulated and insured platform for the trading and yield farming of cryptocurrencies." Expects to approve the deal at the company's general meeting next Tuesday.

----------

IXICO PLC- AI data analytics company based in London - Reports revenue of GBP9.2 million in the year ended September 30, down 3.2% from GBP9.5 million a year prior but 5.7% above market expectations of GBP8.7 million. Expects earnings before interest, tax, depreciation and amortisation of GBP1.2 million, in line with market expectations but slightly below the GBP1.3 million taken a year earlier. Notes that this reflects the GBP7.1 million adverse impact of lost revenue from the end of its Huntington's Disease trial in March. Expects lower profitability in financial 2022 as the company invests in long-term sustained growth.

----------

7digital Group PLC - London-based music licensing provider - Secures GBP1 million expansion to revolving credit facility with Investec Bank. Brings total facility with Investec up to GBP2 million total. Says the enlarged facility matures in September 2023, in keeping with the original terms agreed with the bank in September 2020. Issues 5.4 million warrants with an excise price of 0.55 pence and a lifespan of 36 months, as an arrangement fee to Investec.

----------

Artisanal Spirits Co PLC - Edinburgh, Scotland-based owner of the Scotch Malt Whisky Society - Signs 10-year lease for a new supply chain facility in Uddingston, Scotland. Says the 37,000 square foot facility will provide the company with greater control over its supply chain, in order to improve its margins over time. It includes warehousing, production and office space, with equipment due to be installed in early 2022. The facility is scheduled to become fully operation in the second half of 2022, the company adds.

----------

Destiny Pharma PLC - Brighton, England-based clinical stage biotechnology company focused on life threatening infections - Says US hospital-based study supports potential of XF-73 nasal product to reduce intensive care unit infections. The phase 4 study includes 300,000 patients and shows 23% of all ICU infections are caused by the staphylococcus aureus bacteria. Proposes its XF-73 product as an alternative to mupirocin for these infections. Notes current regulatory talks concerning phase 3 studies to obtain marketing approval for XF-73 in the US and Europe.

----------

ReNeuron Group PLC - Bridgend, Wales-based exosome therapeutics company - Sees first subject treated at Oxford Eye Hospital in a Phase 2a RP trial of its therapeutic candidate for retinitis pigmentosa, a degenerative eye disease. The study uses 2 million cell doses on subjects with some remaining vision, despite having advanced retinitis pigmentosa. Appoints Catherine Isted as chief financial officer and executive director. Notes the departure of non-executive director Chris Evans as he approaches non-independent status after nine years on the board.

----------

Hemogenyx Pharmaceuticals PLC - London-based developer of drugs for blood diseases - Leases custom laboratory at the Mink Building in New York from The Janus Property Co. Says the new laboratory is close to Columbia University and City College, possibly easing future collaboration. The 10,000 square foot laboratory includes two purpose built clean rooms. The company says the new space will be used to pursue commercialisation of its major cell therapy product candidates by manufacturing cells in-house, starting with its HEMO-CAR-T treatment for acute myeloid leukemia.

----------

Corcel PLC - London-based mineral explorer and developer with interests in battery metals and flexible energy generation & storage - Acquires Wo Wo Gap Nickel-Cobalt project in Papua New Guinea. Says it acquired the project as it reached a share purchase agreement with Resource Mining Corp Ltd to acquire the entire issued share capital of the project's owner Niugini Nickel Pty Ltd. "Near term priorities at Wo Wo gap will include resource updates, exploring synergies with our Mambare project, and the early securing of long term shipping and offtake arrangements," says Corcel's executive chair James Parsons.

----------

IGas Energy PLC - Lincoln-based oil and gas producer - Agrees head of terms with Iona Capital Ltd to develop utility scale solar farms in the UK. Initially plans to develop a 25 to 40 megawatt solar farm in southern England, the first of several similar projects. "IGas will contribute its planning and infrastructure expertise, whilst Iona will provide non-recourse project finance. During the development phase, costs will be shared and throughout the project lifecycle, IGas and Iona will each own 50% of the project," the company says.

----------

Gem Diamonds Ltd - London-based miner - Recovers high quality Type 2, 245 carat Type 2 and 102 carat white diamonds. Says it uncovered the stones from the Letseng mine in Lesotho, "the highest dollar per carat kimberlite diamond mine in the world".

----------

Ethernity Networks Ltd - Networking and security solutions provider based in Israel - Secures USD3 million order with Chinese broadband network OEM. Says the order is for customised FPGA system-on-chip processors and covers 2022 and 2023. Expecs further orders thereafter. Under the terms of the agreement, the company will supply OEM with its system-on-chip devices with support for four Gigabit Passive Optical Networking Optical Line Termination ports and four 10Gbps XGS-PON OLT MAC ports by the second quarter of 2022. These products support OEM's 5G and fibre access developments.

----------

Castillo Copper Ltd - Australia and Zambia-focused base metal copper exploration company - Begins drilling at its Arya Copper Prospect in the Mount Isa region of Queensland, Australia. Says drilling follows a significant logistical effort to prepare the drill-pads, heli-lift and other equipment at the site. Plans to drill five initial holes as "proof of concept" at the Arya site and expects to expand the campaign to fully test the area. Focuses drilling on targets identified by BHP in the 1990s, including EG01, EG02 and EG101,2. Notes large a potential 130 metre-thick sulphide bedrock conductor at the EG01 target. Says initial observations are encouraging. Notes concurrent rock chip sampling campaign to extend the known surface anomaly to the south.

----------

React Group PLC - South Derbyshire, England-based cleaning, hygiene and decontamination firm - Wins GBP230,000 contract to provide specialist deep cleaning services for a rail sector client. The contract runs for 25-weeks through to the end of March 2022, the company adds. "Securing this contract highlights the quality and depth of work being provided by the specialist teams within the group and continues to strengthen our presence in the rail sector," says Chief Executive Shaun Doak.

----------

Home REIT PLC - London-based real estate investment trust - Spends GBP166.4 million on property pipeline. Acquires 23 portfolios including 366 properties across England and Wales. Funds the purchases with proceeds from its oversubscribed GBP350 million equity issue in September. Says its total property pipeline totals GBP400 million.

----------

By Scarlett Butler; scarlettbutler@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
29 Feb 2024 14:04

Hemogenyx Pharmaceuticals raises money for leukaemia treatment

(Alliance News) - Hemogenyx Pharmaceuticals PLC on Thursday said it has raised GBP3.3 million through a placing.

Read more
16 Feb 2024 11:27

Hemogenyx shares rise on potential for CBR to treat brain diseases

(Alliance News) - Hemogenyx Pharmaceuticals PLC on Friday said research has shown that its proprietary chimeric bait receptor can be delivered into the brain through programmed microglial cells and could be used for the treatment of brain cancers and some neurodegenerative diseases.

Read more
14 Feb 2024 10:14

Hemogenyx says CBR can be used intranasally to treat viral infections

(Alliance News) - Hemogenyx Pharmaceuticals PLC on Wednesday said its chimeric bait receptor can be delivered intranasally in the form of messenger RNA for the "potential" treatment of airborne viral infections.

Read more
9 Feb 2024 10:00

IN BRIEF: Hemogenyx shares surge as FDA lifts Hemo-Car-T trial hold

Hemogenyx Pharmaceuticals PLC - London-based biopharmaceutical company focused on treatments for deadly blood diseases - US Food & Drug Administration has lifted clinical hold on company's investigational new drug application for Hemo-Car-T to treat acute myeloid leukemia. FDA placed therapy on clinical hold in July due to a splicing deficiency during manufacture of the lentivirus used to produce Car-T cells. Hemogenyx in August produced a "detailed plan, supported by laboratory tests" to address FDA's concerns, which was accepted the following month.

Read more
2 Feb 2024 10:44

IN BRIEF: Hemogenyx hails US patent application progress

Hemogenyx Pharmaceuticals PLC - London-based biopharmaceutical company focused on treatments for deadly blood diseases - Celebrates as patent application is allowed by the US Patent & Trademark Office. The patent is for the process of eliminating hematopoietic stem cells or hematopoietic progenitors in a patient using bi-specific antibodies.

Read more
16 Jan 2024 11:13

Hemogenyx Pharmaceuticals sends complete response on HEMO-CAR-T to FDA

(Alliance News) - Hemogenyx Pharmaceuticals PLC on Tuesday said it submitted a complete response to the previously announced clinical hold of the investigational new drug application to the US Food & Drug Administration.

Read more
8 Jan 2024 10:56

Hemogenyx Pharmaceuticals completes process qualification run

(Alliance News) - Hemogenyx Pharmaceuticals PLC on Monday said it completed a process qualification run.

Read more
28 Nov 2023 16:53

TRADING UPDATES: Upland Resources completes technical study at Sarawak

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
27 Nov 2023 10:52

Hemogenyx shares up as says CBR platform a potential cancer treatment

(Alliance News) - Hemogenyx Pharmaceuticals PLC on Monday said its chimeric based receptor platform could "potentially" be used to treat cancer and viral diseases.

Read more
15 Nov 2023 15:43

Hemogenyx Pharmaceuticals completes lentivirus re-manufacture

(Alliance News) - Hemogenyx Pharmaceuticals PLC on Wednesday said it has completed the re-manufacturing of an improved lentivirus devoid of splice variants.

Read more
28 Sep 2023 14:24

EARNINGS: Dar Global profit multiplies, Hemogenyx loss widens

(Alliance News) - The following is a round-up of earnings updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
18 Sep 2023 14:37

TRADING UPDATES: Avingtrans buys Adaptix, TPXimpact sells Questers

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

Read more
18 Sep 2023 13:00

Hermogenyx shares soar on new partnership with Prevail Partners

(Sharecast News) - Shares in biopharma group Hemogenyx surged on Monday after the company received a $0.83m investment from Prevail Partners as it continues to work on its planned clinical trial for leukaemia treatment.

Read more
14 Sep 2023 14:31

Hemogenyx Pharma says US FDA accepts Hemo-Car-T clinical hold lift plan

(Alliance News) - Hemogenyx Pharmaceuticals PLC on Thursday said the US Food & Drug Administration has accepted its plan to address concerns which sparked a clinical hold on its chimeric antigen receptor T-cell or Hemo-Car-T therapy.

Read more
8 Sep 2023 19:43

IN BRIEF: Hemogenyx Pharmaceuticals says patent number published

Hemogenyx Pharmaceuticals PLC - London-based biopharmaceutical group developing new therapies and treatments for blood diseases - Says its patent application number "WO2023168292 Chimeric Bait Receptors and Uses Thereof" was published by the World Intellectual Property Organization on Thursday. Says it remains to be reviewed and approved by national patent authorities.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.